Study of XL999 in Patients With Metastatic Colorectal Cancer

Inclusion Criteria:

• Males and females with histologically confirmed metastatic colorectal cancer

• Measurable disease according to Response Criteria for Solid Tumors (RECIST)

• At least 1 prior therapeutic regimen (chemotherapy or biologic)

• ECOG performance status of 0 or 1

• Life expectancy ≥3 months

• Adequate organ and marrow function

• No other malignancies within 5 years

• Signed informed consent

Exclusion Criteria:

• Radiation to ≥25% of bone marrow within 30 days of XL999 treatment

• Treatment with systemic anticancer therapy within 30 days of XL999 treatment

• Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverseevents due to other medications administered >30 days prior to study enrollment

• History of or known brain metastases, current spinal cord compression, orcarcinomatous meningitis

• Uncontrolled and/or intercurrent illness

• Pregnant or breastfeeding females

• Known HIV